Disclosed herein is the use a cyanobacterial biomass for treating hepatitis B virus (HBV) infection, in particular, chronic HBV infection. According to various embodiments of the present disclosure, the cyanobacterial biomass, upon administration of at least one month, significantly reduces the level of the surface antigen of hepatitis B virus (HBsAg) detectable in the subject receiving the treatment and/or mitigates insomnia associated with chronic HBV infection.

A composition for enhancing human immune system may include (i) Herba lysimachiae 0.05-0.3%; (ii) Herba lysimachiae 8-45%; (iii) Herba lysimachiae doederleinii hieron 8-45%; (iv) Folium artmisiae argyi 0.05-0.3%; (v) Herba hedyotis diffusae 0.05-0.3%; (vi) Herba hyperici japonici 5-25%; (vii) Half-branched lotus herba scutelbrice barbata 0.05-0.2%; and (viii) Prunellae vulgaris 10-30%, including water extracted powder or concentrated liquid, paste, etc.

A composition for enhancing human immune system may include (i) Herba lysimachiae 0.05-0.3%; (ii) Herba lysimachiae 8-45%; (iii) Herba lysimachiae doederleinii hieron 8-45%; (iv) Folium artmisiae argyi 0.05-0.3%; (v) Herba hedyotis diffusae 0.05-0.3%; (vi) Herba hyperici japonici 5-25%; (vii) Half-branched lotus herba scutelbrice barbata 0.05-0.2%; and (viii) Prunellae vulgaris 10-30%, including water extracted powder or concentrated liquid, paste, etc.

The present disclosure relates to the technical field of liver-protecting ingredient preparation processes, and particularly to a process for preparing an efficient liver-protecting compound ingredient. The process comprises an internal drug and an external drug, wherein the internal drug comprises 65 g of astragalus membranaceus, 65 g of Salvia miltiorrhiza, 50 g of Ligustrum lucidum, 50 g of the fruit of Chinese wolfberry, 50 g of Tuckahoe, 40 g of radix bupleuri, 40 g of Schisandra chinensis, 40 g of Codonopsis pilosula, 40 g of Pinellia ternata, 40 g of rhizoma dioscoreae, 40 g of radix isatidis, 40 g of Atractylodes macrocephala, 40 g of radix curcumae, 40 g of Radix Paeoniae Alba, 40 g of Hedyotis diffusa, 40 g of Angelica sinensis, 40 g of pericarpium citri reticulatae, 40 g of honeysuckle, 40 g of rhizoma polygonati, and 30 g of parched hawthorn fruit.

The present disclosure relates to the technical field of liver-protecting ingredient preparation processes, and particularly to a process for preparing an efficient liver-protecting compound ingredient. The process comprises an internal drug and an external drug, wherein the internal drug comprises 65 g of astragalus membranaceus, 65 g of Salvia miltiorrhiza, 50 g of Ligustrum lucidum, 50 g of the fruit of Chinese wolfberry, 50 g of Tuckahoe, 40 g of radix bupleuri, 40 g of Schisandra chinensis, 40 g of Codonopsis pilosula, 40 g of Pinellia ternata, 40 g of rhizoma dioscoreae, 40 g of radix isatidis, 40 g of Atractylodes macrocephala, 40 g of radix curcumae, 40 g of Radix Paeoniae Alba, 40 g of Hedyotis diffusa, 40 g of Angelica sinensis, 40 g of pericarpium citri reticulatae, 40 g of honeysuckle, 40 g of rhizoma polygonati, and 30 g of parched hawthorn fruit.

The present invention discloses a method for extraction and preparation of curcumin, and in particular relates to the technical field of preparation of curcumin, which comprises the following steps: S1S9. For the present invention, the preparation process is simple, in which the curcumin can be fully utilized, the waste of raw materials can be minimized, and the nutritional elements of curcumin may be enriched to enhance its efficacy safely without toxic or side effect.

The present invention discloses a method for extraction and preparation of curcumin, and in particular relates to the technical field of preparation of curcumin, which comprises the following steps: S1S9. For the present invention, the preparation process is simple, in which the curcumin can be fully utilized, the waste of raw materials can be minimized, and the nutritional elements of curcumin may be enriched to enhance its efficacy safely without toxic or side effect.

The present invention relates to the field of medicines, in particular to an anti-tumor effective component of Hedyotis diffusa, a preparation method therefor and the use thereof. Provided in the present invention is the use of one or a combination of kaempferol-3-O-[2-O-(6-O-E-feruloyl)--D-glucopyranose]--D-pyranose and E-6-O-p-coumaroylpaederoside methyl ester in tumor resistance or the preparation of an anti-tumor drug. The research of the present invention has shown that both a kaempferol-3-O-[2-O-(6-O-E-feruloyl)--D-glucopyranose]--D-pyranose compound monomer and an E-6-O-p-coumaroylpaederoside methyl ester compound monomer have very strong anti-tumor activity. In the in-vivo anti-tumor activity research, the inhibition rates thereof can reach 48.97% and 45.96%, respectively; and when both are combined to inhibit tumor cells, the research reveals that the two monomers have an obvious effect of synergistically inhibiting tumors.

The present invention relates to the field of medicines, in particular to an anti-tumor effective component of Hedyotis diffusa, a preparation method therefor and the use thereof. Provided in the present invention is the use of one or a combination of kaempferol-3-O-[2-O-(6-O-E-feruloyl)--D-glucopyranose]--D-pyranose and E-6-O-p-coumaroylpaederoside methyl ester in tumor resistance or the preparation of an anti-tumor drug. The research of the present invention has shown that both a kaempferol-3-O-[2-O-(6-O-E-feruloyl)--D-glucopyranose]--D-pyranose compound monomer and an E-6-O-p-coumaroylpaederoside methyl ester compound monomer have very strong anti-tumor activity. In the in-vivo anti-tumor activity research, the inhibition rates thereof can reach 48.97% and 45.96%, respectively; and when both are combined to inhibit tumor cells, the research reveals that the two monomers have an obvious effect of synergistically inhibiting tumors.